RBC Capital upgraded Sage Therapeutics (SAGE) to Sector Perform from Underperform with an unchanged price target of $4. The firm says that this morning’s announced failure of dalzamendor in Huntington’s disease and discontinuation of the program, its thesis on potential stock downside into and through the data readout has played out. The end of the road for dalzamendor means Sage will now have to work through a strategic reset while launching Zurzuvae, the analyst tells investors in a research note. As the company sorts out next steps for its share of Zurzuvae and earlier stage pipeline, RBC expects the shares to trade more in line.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
- Sage Therapeutics reported another clinical setback, says H.C. Wainwright
- Sage Therapeutics reports results from Phase 2 DIMENSION Study
- Acumen appoints Schacterle as Chief Regulatory Officer, Head of Quality
- Sage Therapeutics price target lowered to $9 from $11 at Morgan Stanley